This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Babylon Holdings 미래 성장

Future 기준 확인 0/6

현재 Babylon Holdings 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Healthcare Services 수익 성장	30.8%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

Recent updates

Babylon to execute 1-for-25 reverse share split

Nov 09

Babylon Holdings files to sell 145.89M Class A ordinary shares

Oct 17

Babylon receives NYSE notice and gets approval for reverse share split at a consolidation ratio of between 15 and 25

Sep 22

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Babylon Holdings 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

OTCPK:BBLN.F - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2023	1,154	-256	-278	-271	N/A
12/31/2022	1,110	-221	-320	-311	N/A
9/30/2022	938	-213	-331	-329	N/A
6/30/2022	724	-189	-311	-306	N/A
3/31/2022	516	-96	-293	-289	N/A
12/31/2021	321	-77	-198	-189	N/A
9/30/2021	244	-199	-123	-83	N/A
6/30/2021	186	-172	-113	-76	N/A
3/31/2021	139	-152	-114	-78	N/A
12/31/2020	79	-212	-181	-180	N/A
12/31/2019	16	-140	-182	-144	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BBLN.F 의 예상 수익 증가율이 절약률( 2.2% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: BBLN.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: BBLN.F 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: BBLN.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: BBLN.F 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BBLN.F 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

This company listing is no longer active

Babylon Holdings 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates decrease by 16%, EPS upgraded

Babylon Holdings Limited Provides Unaudited Earnings Guidance for the Year Ended December 31, 2022

Consensus estimates of losses per share improve by 10%

Price target decreased to US$2.10

Babylon Holdings Limited Provides Guidance for the Twelve Months Ending December 31, 2022

Babylon Holdings Limited Provides Earnings Guidance for the Year 2022

Recent updates

Babylon Holdings Limited Filed for Bankruptcy

Babylon Announces the Receipt of Continued Listing Standards Notice from NYSE and Upcoming Delisting

Babylon Holdings Limited Announces Board Changes

Babylon Holdings Limited announced that it expects to receive $34.5 million in funding from AlbaCore Capital LLP

First quarter 2023 earnings released: US$2.53 loss per share (vs US$5.94 loss in 1Q 2022)

Global Chief Medical Officer recently sold US$74k worth of stock

Global Chief Medical Officer recently sold US$74k worth of stock

Consensus revenue estimates decrease by 16%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Babylon Holdings Limited to Report Q4, 2022 Results on Mar 09, 2023

Babylon Holdings Limited Provides Unaudited Earnings Guidance for the Year Ended December 31, 2022

Consensus estimates of losses per share improve by 10%

Price target decreased to US$2.10

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

VNV (Cyprus) Limited Engages in Discussions with Babylon Holdings Limited

Babylon to execute 1-for-25 reverse share split

Babylon Holdings Limited announced that it has received $80 million in funding from VNV Global AB (publ), Kinnevik AB and other investors

Babylon Holdings Limited announced that it expects to receive $61.45 million in funding from VNV Global AB (publ), Kinnevik AB and other investors

Babylon Holdings Limited Announces Resignation of Yon Nuta as Chief Product Officer, Effective October 18, 2022

Babylon Holdings files to sell 145.89M Class A ordinary shares

Babylon Holdings Limited to Report Q3, 2022 Results on Nov 10, 2022

Babylon Holdings Reportedly to Sell Meritage IPA Assets in Early 2023

Babylon Hires Andrew Hine as Vice President of the Europe, Middle East, & Africa & Asia Go-To-Market Team

Babylon Receives Share Price Notice from the New York Stock Exchange Due to Non-Compliance with NYSE Rule 802.01C

Babylon receives NYSE notice and gets approval for reverse share split at a consolidation ratio of between 15 and 25

Babylon Holdings Limited Announces Chief Financial Officer Changes

Babylon gets new CFO

Babylon Holdings Denies Acquisition Rumors

Babylon Holdings jumps after report of potential sale process

Second quarter 2022 earnings: EPS misses analyst expectations

Babylon Holdings Limited Provides Guidance for the Twelve Months Ending December 31, 2022

Babylon Holdings Limited Announces Executive Changes

Babylon Holdings Limited, Annual General Meeting, Sep 14, 2022

Babylon Holdings Limited to Report Q2, 2022 Results on Aug 09, 2022

Babylon Holdings Limited Provides Earnings Guidance for the Year 2022

Babylon +2%, expects $100M savings per year

Consensus revenue estimates increase by 11%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Babylon Holdings Limited Revises Revenue Guidance for the Year 2022

Price target decreased to US$7.30

High number of new and inexperienced directors

Babylon Holdings Limited to Report Q1, 2022 Results on May 12, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues in line with analyst expectations

No longer forecast to breakeven

Babylon Holdings Limited to Report Q4, 2021 Results on Mar 10, 2022

Babylon Holdings Limited Announces Resignation of Stacy Saal as Chief Operating Officer, Effective February 12, 2022

Babylon Holdings: A Virtual Value-Based Care Leader With Upside

Babylon Holdings Limited (NYSE:BBLN) acquired DayToDay Health.

Babylon Holdings Limited Increases Revenue Guidance for the Full-Year 2022

Forecast to breakeven in 2024

High number of new and inexperienced directors

Babylon Launches AI in Rwanda in Next Step Towards Digitising Healthcare in Rwanda

Third quarter 2021 earnings released: US$0.08 loss per share

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견